NASDAQ:ASRT - Nasdaq - US04546C2052 - Common Stock - Currency: USD
ASSERTIO HOLDINGS INC
NASDAQ:ASRT (2/6/2025, 12:49:50 PM)
0.8113
+0.01 (+0.81%)
The current stock price of ASRT is 0.8113 USD. In the past month the price decreased by -8.52%. In the past year, price increased by 0.49%.
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with...
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with...
Same-day dosing results comparable to next day dosing schedules...
CTO Role to Focus on Growth from New Market and Revenue Strategies...
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 85.37 | 824.17B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.23 | 386.96B | ||
JNJ | JOHNSON & JOHNSON | 15.41 | 370.70B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.3 | 228.03B | ||
MRK | MERCK & CO. INC. | 11.68 | 225.67B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.56 | 214.74B | ||
PFE | PFIZER INC | 8.36 | 147.40B | ||
SNY | SANOFI-ADR | 13.43 | 134.70B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 49.95 | 118.54B | ||
ZTS | ZOETIS INC | 30.39 | 78.98B | ||
GSK | GSK PLC-SPON ADR | 7.97 | 75.48B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.92 | 43.13B |
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 53 full-time employees. The firm has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
ASSERTIO HOLDINGS INC
100 S. Saunders Road, Suite 300
Lake Forest ILLINOIS 60045 US
CEO: Daniel A. Peisert
Employees: 53
Company Website: https://www.assertiotx.com/
Investor Relations: https://investor.assertiotx.com/overview/default.aspx
Phone: 12244197106
The current stock price of ASRT is 0.8113 USD.
The exchange symbol of ASSERTIO HOLDINGS INC is ASRT and it is listed on the Nasdaq exchange.
ASRT stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ASRT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ASRT.
ASRT does not pay a dividend.
ASRT does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
The outstanding short interest for ASRT is 6.5% of its float.
ChartMill assigns a fundamental rating of 3 / 10 to ASRT. ASRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ASRT reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -177.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.81% | ||
ROE | -52.47% | ||
Debt/Equity | 0.3 |
ChartMill assigns a Buy % Consensus number of 82% to ASRT. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 84.04% and a revenue growth -20.57% for ASRT